[Expert consensus on urate-lowering therapy for high-risk hyperuricemia (2025 edition)].

Hyperuricemia (HUA) is highly prevalent in China with an increasing prevalence and a growing trend towards the youth. Long-term HUA can lead to gout, kidney stones and renal impairment, and is also associated with the development and progression of other organ damage, including cardiovascular diseases, metabolic disorders, and neurological conditions, etc. To identify high-risk individuals for HUA-related complications and establish standardized management strategies, including determining which HUA patients may be recommended for urate-lowering therapy (ULT) and outlining detailed treatment regimens (such as optimal timing, drug selection and treatment targets, etc.), the Chinese Rheumatology Association and the Committee for Rheumatologists and Immunologists of Chinese Primary Health Care Foundation organized domestic experts to develop the Expert Consensus on Urate-lowering Therapy for High-Risk Hyperuricemia (2025 edition). This consensus systematically summarizes the latest evidence, defines high-risk hyperuricemia (HrHUA) as well as 11 ULT relevant clinical issues, and provides detailed recommendations to treatment practices, ultimately improving patient outcomes.